IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9840512 B1

PDFFull Text
Date of Patent:
Dec. 12, 2017

Filed:

Feb. 20, 2014

Antidiabetic bicyclic compounds

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Linda L. Brockunier, Orange, NJ (US);

Helen Chen, Marlboro, NJ (US);

Harry R. Chobanian, Aberdeen, NJ (US);

Matthew J. H. Clements, Old Bridge, NJ (US);

Alejandro Crespo, Edison, NJ (US);

Duane E. DeMong, Somerset, NJ (US);

Yan Guo, Westfield, NJ (US);

William K. Hagmann, Westfield, NJ (US);

Karen M. Marcantonio, New York, NY (US);

Michael Miller, Scotch Plains, NJ (US);

Barbara Pio, West Orange, NJ (US);

Christopher W. Plummer, Hoboken, NJ (US);

Dong Xiao, Warren, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Baerbel R. Brown

Catherine D. Fitch

Primary Examiner:

Deepak Rao

Assistant Examiner:

Laura Daniel

Int. Cl.
CPC ...
C07D 311/04 (2006.01); C07D 311/28 (2006.01); C07D 491/052 (2006.01); C07D 493/04 (2006.01); C07D 201/00 (2006.01); C07D 405/14 (2006.01); C07D 319/20 (2006.01); C07D 405/04 (2006.01); C07D 405/06 (2006.01); C07D 405/10 (2006.01); C07D 413/10 (2006.01); C07D 417/04 (2006.01); C07D 491/048 (2006.01); A61K 31/352 (2006.01); A61K 31/416 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/436 (2006.01); A61K 31/4433 (2006.01); A61K 31/444 (2006.01); A61K 31/497 (2006.01); A61K 31/538 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 493/04 (2013.01); A61K 31/352 (2013.01); A61K 31/416 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/436 (2013.01); A61K 31/444 (2013.01); A61K 31/4433 (2013.01); A61K 31/497 (2013.01); A61K 31/538 (2013.01); A61K 45/06 (2013.01); C07D 201/00 (2013.01); C07D 311/04 (2013.01); C07D 311/28 (2013.01); C07D 319/20 (2013.01); C07D 405/04 (2013.01); C07D 405/06 (2013.01); C07D 405/10 (2013.01); C07D 405/14 (2013.01); C07D 413/10 (2013.01); C07D 417/04 (2013.01); C07D 491/048 (2013.01); C07D 491/052 (2013.01);
Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Find Patent Forward Citations

Loading…